Debra Monticciolo, MD, who has previously led both the Society of Breast Imaging and the American College of Radiology, discussed how different screening strategies may impact patient outcomes.

Finerenone, sold under the brand name Kerendia, is already approved by the FDA for reducing heart and kidney risks in patients with chronic kidney disease (CKD) and type 2 diabetes. Bayer plans on presenting the new data in full at ESC Congress 2024 in London. 

The AMA applauded the Texas Medical Association for defeating dozens of scope of practice creep bills in the Texas legislature this year.

Dana Smetherman, MD, is a diagnostic radiologist who specializes in breast imaging. She spoke to Health Imaging about some key issues that have her attention in 2024 and beyond. 

Bharath Krishnamurthy, a director of health policy and analytics at the American Hospital Association, explains the financial impact of current healthcare staffing shortages.

LVOT obstruction after TMVR remains a significant concern among structural heart cardiologists. Predicting the risk of LVOT obstruction typically requires CT, which comes with certain disadvantages compared to other imaging options.

Individuals are 83% more likely to be diagnosed with a psychiatric disorder within one year of a CVD hospitalization, according to new data published in the Journal of the American Heart Association.

The Equitable Community Access to Pharmacist Services Act would allow Medicare to reimburse for certain pharmacist-administered tests, treatments and vaccinations.